$MRNA News

Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”

Moderna CEPI Ebola Vaccine Work Highlights Broader Infectious Disease Ambitions

MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus

UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts

Moderna to Present at Upcoming Conference in June 2026

Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript

Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data - Slideshow

Moderna CEO Stephane Bancel on INT trial results: There's duration of efficacy which is exciting

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

Moderna Joins Global Initiative to Advance Vaccine Candidate for Bundibugyo Ebola Virus (MRNA)

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

Moderna Expands Partnership to Develop Vaccine for Rare Ebola Virus Strain, CEPI Commits Up to $50M to Support Early Testing and Manufacturing of Experimental Ebola Shot

Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine

Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue Rules - What's Changed

MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot

Moderna Flu Shot Heads To FDA Advisory Panel

'FDA Plans Rare Advisory Hearing to Debate Moderna's Flu Shot' - Bloomberg

Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ...

Roivant Sciences Q4 Earnings Call Highlights